TimeTeller Saliva Test Targets Circadian Cancer Care
TimeTeller’s saliva test maps circadian rhythms, while clinical studies explore timing cancer drugs to cut side effects and improve treatment outcomes.
Summary
German startup TimeTeller sells an at-home saliva test that maps individual circadian rhythms for personalized guidance on sleep, nutrition, light exposure and physical activity. CEO Angela Relógio, a physicist-engineer and molecular biologist with research experience in oncology, circadian biology and systems medicine, developed the test after observing cancer patients interrupt treatment because of side effects. She personally funded its first patent and presented the company at Startup Battlefield in San Francisco on October 14, 2026.
TimeTeller’s long-term goal is to identify when individual cancer medicines will be most effective and best tolerated, but its consumer kit cannot prescribe treatment timing. Each drug requires calculations validated through clinical studies. The company, founded with biochemist and market access specialist Benjamin Dose, spun out of Berlin’s Charité university hospital before moving to Medical School Hamburg, which supplied patients, funding and backup employment for its 10-person team. Techniker Krankenkasse reimburses the test for some cancer patients, and the partners are preparing to extend access among the insurer’s 12 million members. Potential future uses include diabetes, Alzheimer’s, performance and women’s health, although cancer remains the core mission.
Positives
- Techniker Krankenkasse reimburses TimeTeller testing for some cancer patients and is preparing wider access across its 12 million members.
- Medical School Hamburg provides TimeTeller with patient access, funding and backup employment for its 10-person team.
- TimeTeller’s saliva test already supports personalized recommendations covering sleep, nutrition, light exposure and physical activity.
- Angela Relógio personally funded the first patent to move her circadian oncology discovery beyond academic publication.
- Clinical studies could establish medicine-specific treatment times that improve cancer drug tolerance and effectiveness.
Risks & concerns
- TimeTeller’s direct-to-consumer kit cannot tell cancer patients when to take individual medicines.
- Every cancer drug requires separate calculations and clinical validation before treatment timing can be recommended.
- Cancer patients currently interrupt or restart treatment because of side effects, the problem that prompted TimeTeller’s development.
- TimeTeller’s team required backup employment from Medical School Hamburg in case the startup could not pay them.
- Applications in diabetes, Alzheimer’s, performance and women’s health remain potential uses rather than established offerings.